Immunological configuration of ovarian carcinoma: features and impact on disease outcome.
female
genital neoplasms
immunologic surveillance
immunotherapy
tumor biomarkers
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
accepted:
09
09
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
13
1
2022
Statut:
ppublish
Résumé
Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.
Identifiants
pubmed: 34645669
pii: jitc-2021-002873
doi: 10.1136/jitc-2021-002873
pmc: PMC8515436
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : BLRD VA
ID : I01 BX004974
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208753
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JF and RS are employees of Sotio Biotech a.s.; IV declares consulting for Astra Zeneca, Clovis Oncology, Carrick Therapeutics, Deciphera Pharmaceuticals, Elevar Therapeutics, F. Hoggmann-La Roche, Genmab, GSK, Immunogen, Jazzpharma, Mersana, Millennium Pharmaceuticals, MSD, Novocure, Octimet Oncology NV, Oncoinvent AS, Sotio a.s., Verastem Oncology, Zentalis; contracted research for Oncoinvent AS, Genmab; research funding from Amgen, Roche; LG declares research funding from Lytix and Phosplatin (completed) and speaker and/or advisory honoraria from Boehringer Ingelheim, Astra Zeneca, OmniSEQ, The Longevity Labs, Inzen, Onxeo, the Luke Heller TECPR2 Foundation; SO has patents for molecular signatures in ovarian cancer (US10253368 and EU2908913) and is funded by NCI (R01 CA208753) and VA (VA-ORD BX004974) grants. AC declares consulting for SOTIO; contracted research for Novocure and Oncoinvent.
Références
Acta Oncol. 2020 Jun;59(6):652-659
pubmed: 31931651
Front Immunol. 2021 Jan 25;11:613773
pubmed: 33584699
Front Immunol. 2019 Jun 04;10:1273
pubmed: 31214202
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Front Genet. 2020 Apr 30;11:369
pubmed: 32425977
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Int Rev Cell Mol Biol. 2019;349:177-211
pubmed: 31759431
Nat Med. 2001 Dec;7(12):1339-46
pubmed: 11726975
PLoS One. 2013 Dec 06;8(12):e79769
pubmed: 24324582
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Technol Cancer Res Treat. 2013 Jun;12(3):259-67
pubmed: 23289476
Int J Cancer. 2016 Oct 15;139(8):1894-903
pubmed: 27299695
Nature. 2018 Jun;558(7710):454-459
pubmed: 29899446
Nat Commun. 2015 Jan 23;6:6072
pubmed: 25614966
J Clin Invest. 2011 Aug;121(8):3206-19
pubmed: 21737876
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Nat Med. 2021 Feb;27(2):212-224
pubmed: 33574607
Cancer Res. 2012 Jan 1;72(1):66-75
pubmed: 22065722
Int J Clin Exp Pathol. 2015 Aug 01;8(8):9428-33
pubmed: 26464699
Cancer Res. 2011 Aug 15;71(16):5423-34
pubmed: 21697280
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Oncoimmunology. 2019 Jul 18;8(11):e1638212
pubmed: 31646087
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33452206
Cell Metab. 2019 Jan 8;29(1):141-155.e9
pubmed: 30174305
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Cancer Sci. 2014 Aug;105(8):966-73
pubmed: 24826982
Mol Carcinog. 2016 Nov;55(11):1688-1699
pubmed: 26457987
Cancer Immunol Res. 2018 Dec;6(12):1578-1592
pubmed: 30396909
Future Oncol. 2018 Sep;14(21):2103-2113
pubmed: 29584456
Oncol Rep. 2018 May;39(5):2081-2090
pubmed: 29565447
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Vaccines (Basel). 2020 Nov 05;8(4):
pubmed: 33167428
Gynecol Oncol. 2006 Sep;102(3):542-5
pubmed: 16510173
Science. 2012 Sep 28;337(6102):1678-84
pubmed: 23019653
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cell Rep. 2018 Feb 13;22(7):1875-1888
pubmed: 29444438
Annu Rev Immunol. 2020 Apr 26;38:541-566
pubmed: 32017635
Mol Cancer Ther. 2007 Jul;6(7):1993-2002
pubmed: 17620429
PLoS One. 2015 Feb 06;10(2):e0118080
pubmed: 25658637
Front Immunol. 2019 Apr 03;10:691
pubmed: 31001284
Mol Cancer. 2016 Sep 09;15(1):58
pubmed: 27613122
Cancer Res. 2007 Sep 15;67(18):8900-5
pubmed: 17875732
J Immunol. 2010 May 15;184(10):5654-62
pubmed: 20400704
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Cancer Res. 2012 May 1;72(9):2162-71
pubmed: 22549946
Clin Cancer Res. 2014 Jul 15;20(14):3818-29
pubmed: 24916698
J Leukoc Biol. 2013 Mar;93(3):343-52
pubmed: 23136258
Cancer Res. 2018 Oct 15;78(20):5891-5900
pubmed: 30104241
Mol Ther Oncolytics. 2019 Mar 27;13:67-81
pubmed: 31020037
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33476307
Oncotarget. 2016 Jul 12;7(28):44534-44544
pubmed: 27322208
Int Rev Cell Mol Biol. 2019;348:179-215
pubmed: 31810553
J Immunother Cancer. 2019 Nov 20;7(1):312
pubmed: 31747968
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Anticancer Res. 2019 Nov;39(11):5953-5962
pubmed: 31704820
J Clin Oncol. 2017 Jul 1;35(19):2193-2202
pubmed: 28471727
Neoplasia. 2011 May;13(5):393-405
pubmed: 21532880
Clin Cancer Res. 2017 Jan 15;23(2):587-599
pubmed: 27401249
Oncoimmunology. 2012 May 1;1(3):380-382
pubmed: 22737622
Int Rev Cell Mol Biol. 2019;342:149-173
pubmed: 30635090
J Transl Med. 2020 Jun 1;18(1):220
pubmed: 32487171
Int J Cancer. 2013 Mar 1;132(5):1070-9
pubmed: 22865582
Oncotarget. 2017 Oct 6;8(56):96035-96047
pubmed: 29221185
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
BMC Cancer. 2013 Sep 17;13:422
pubmed: 24044611
Cancer Res. 2011 Dec 15;71(24):7463-70
pubmed: 22025564
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
J Clin Invest. 1995 May;95(5):2391-6
pubmed: 7738202
Cancer Immunol Immunother. 2015 Dec;64(12):1495-504
pubmed: 26298430
Cancers (Basel). 2018 Oct 29;10(11):
pubmed: 30380628
Cancer Discov. 2020 Dec;10(12):1808-1825
pubmed: 33139244
Gynecol Oncol. 2009 Nov;115(2):185-92
pubmed: 19665763
Tumour Biol. 2017 Jul;39(7):1010428317712592
pubmed: 28718374
J Cancer. 2017 Aug 25;8(15):2915-2923
pubmed: 28928882
Ann Oncol. 2017 May 1;28(5):996-1004
pubmed: 28453702
Cancer Immunol Res. 2016 Apr;4(4):303-11
pubmed: 26817996
Br J Cancer. 2009 Jan 13;100(1):134-44
pubmed: 19088723
Oncotarget. 2016 Nov 15;7(46):75130-75144
pubmed: 27650547
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Gynecol Oncol. 2010 May;117(2):366-72
pubmed: 20144842
Cells. 2020 Jan 27;9(2):
pubmed: 32012728
Clin Cancer Res. 2005 Dec 1;11(23):8326-31
pubmed: 16322292
Nat Commun. 2018 Apr 27;9(1):1685
pubmed: 29703902
Anticancer Res. 2012 Dec;32(12):5233-8
pubmed: 23225421
Cancer Res. 2013 Aug 15;73(16):5016-28
pubmed: 23824740
Cancer Res. 2019 Oct 1;79(19):5034-5047
pubmed: 31409640
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
J Exp Med. 2013 Jul 1;210(7):1433-445
pubmed: 23797095
Clin Cancer Res. 2017 Jan 1;23(1):250-262
pubmed: 27354470
Cancer Res. 2013 Aug 1;73(15):4653-62
pubmed: 23761327
Br J Cancer. 2016 Aug 23;115(5):553-63
pubmed: 27490802
Neoplasia. 2013 Apr;15(4):409-20
pubmed: 23555186
J Clin Oncol. 2019 Sep 20;37(27):2460-2471
pubmed: 31403857
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
Cell Metab. 2019 Jun 4;29(6):1376-1389.e4
pubmed: 30930171
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
J Ovarian Res. 2016 Apr 06;9:21
pubmed: 27048364
JAMA Oncol. 2019 Aug 1;5(8):1141-1149
pubmed: 31194228
PLoS One. 2012;7(6):e38541
pubmed: 22685580
Oncoimmunology. 2018 Jul 30;7(12):e1474318
pubmed: 30524884
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
Biochem Biophys Res Commun. 2016 Feb 19;470(4):947-54
pubmed: 26826383
J Clin Oncol. 2018 Jun 10;36(17):1658-1667
pubmed: 28981385
Sci Rep. 2020 Apr 8;10(1):6096
pubmed: 32269279
Sci Rep. 2019 Feb 21;9(1):2527
pubmed: 30792527
Cancer Discov. 2012 Dec;2(12):1100-8
pubmed: 23171795
Oncoimmunology. 2015 Jan 22;4(4):e1001224
pubmed: 26137398
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Ovarian Res. 2014 Feb 08;7:19
pubmed: 24507759
Int J Gynecol Cancer. 2009 Dec;19(9):1487-93
pubmed: 19955923
Clin Cancer Res. 2019 Aug 1;25(15):4820-4831
pubmed: 31076549
Int Rev Cell Mol Biol. 2019;342:73-93
pubmed: 30635094
Nat Med. 2020 Aug;26(8):1271-1279
pubmed: 32572264
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Oncoimmunology. 2021 Feb 19;10(1):1889101
pubmed: 33659100
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancer Cell. 2020 Feb 10;37(2):226-242.e7
pubmed: 32049047
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
JAMA Oncol. 2021 Jan 1;7(1):78-85
pubmed: 33211063
Int Rev Cell Mol Biol. 2019;349:55-151
pubmed: 31759434
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Nat Rev Clin Oncol. 2021 Jun;18(6):379-393
pubmed: 33633361
Cancer Discov. 2021 Jan;11(1):34-44
pubmed: 33277307
JAMA Oncol. 2019 Dec 1;5(12):1731-1738
pubmed: 31600397
Oncoimmunology. 2018 Sep 26;7(12):e1502905
pubmed: 30524900
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Pharmacol Ther. 2019 Aug;200:55-68
pubmed: 30998941
Oncotarget. 2018 Oct 5;9(78):34810-34820
pubmed: 30410679
Nat Commun. 2018 Jul 26;9(1):2923
pubmed: 30050129
Nat Rev Cancer. 2020 Aug;20(8):437-454
pubmed: 32581320
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Oncogene. 2017 Jan 12;36(2):168-181
pubmed: 27292260
Cancer Cell. 2021 Mar 8;39(3):310-345
pubmed: 33338426
Cell Rep. 2021 May 25;35(8):109165
pubmed: 34038734
J Clin Invest. 2009 Oct;119(10):3011-23
pubmed: 19741298
Clin Cancer Res. 2011 Sep 15;17(18):6083-96
pubmed: 21795409
J Clin Invest. 2018 Feb 1;128(2):589-606
pubmed: 29251630
Cancer Microenviron. 2014 Aug;7(1-2):33-9
pubmed: 24214412
Cancer Microenviron. 2013 Aug;6(2):147-57
pubmed: 23104434
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32819974
Cancer Cell. 2021 Jul 12;39(7):928-944.e6
pubmed: 33961783
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Cancer Res. 2005 Dec 1;65(23):10794-800
pubmed: 16322225
Oncotarget. 2017 Feb 14;8(7):12389-12405
pubmed: 27852039
Front Immunol. 2019 Aug 09;10:1782
pubmed: 31456796
Nat Rev Clin Oncol. 2021 Apr;18(4):197-198
pubmed: 33686265
J Immunol. 2008 Jun 1;180(11):7338-48
pubmed: 18490733
Cancer Discov. 2018 Mar;8(3):304-319
pubmed: 29196464
Nat Commun. 2020 Mar 13;11(1):1364
pubmed: 32170086
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
J Exp Med. 2003 Aug 18;198(4):569-80
pubmed: 12925674
Cancer Immunol Immunother. 2009 Mar;58(3):449-59
pubmed: 18791714
J Immunol. 2014 Nov 15;193(10):4952-61
pubmed: 25305322
PLoS One. 2009;4(4):e4992
pubmed: 19352430
Clin Biochem. 2004 May;37(5):363-9
pubmed: 15087251
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Br J Cancer. 2009 Nov 3;101(9):1513-21
pubmed: 19861998
Cell Res. 2021 Jan;31(1):5-16
pubmed: 32733014
Cell Mol Immunol. 2021 May;18(5):1085-1095
pubmed: 33785843
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
Cancer Cell. 2014 Dec 8;26(6):938
pubmed: 28898680
Cell. 2016 May 19;165(5):1092-1105
pubmed: 27133165
Cell Metab. 2019 Jul 2;30(1):36-50
pubmed: 31269428
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
Cancer Res. 2018 Apr 1;78(7):1779-1791
pubmed: 29374065
Clin Cancer Res. 2018 Nov 15;24(22):5685-5696
pubmed: 30065096
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Cell Rep. 2017 Oct 3;21(1):154-167
pubmed: 28978469
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
PLoS One. 2014 Nov 03;9(11):e111757
pubmed: 25365237
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33589520
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
J Clin Invest. 2012 Oct;122(10):3603-17
pubmed: 22945634
J Immunother Cancer. 2018 Dec 4;6(1):139
pubmed: 30526667
Gynecol Oncol. 2006 Oct;103(1):226-33
pubmed: 16631235
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
Cancer Gene Ther. 2015 Mar;22(4):198-206
pubmed: 25721210
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Oncoimmunology. 2018 Mar 15;7(5):e1424672
pubmed: 29721385
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
J Clin Invest. 2019 Mar 1;129(3):1211-1228
pubmed: 30589644
Cancer Res. 2012 Oct 15;72(20):5240-9
pubmed: 22850422
Oncotarget. 2017 Aug 10;8(44):76843-76856
pubmed: 29100353
Cancer Res. 2018 May 1;78(9):2343-2355
pubmed: 29437708
Immunity. 2013 Sep 19;39(3):611-21
pubmed: 24012420
Clin Immunol. 2011 Dec;141(3):338-47
pubmed: 21955569
Gynecol Oncol. 2015 Aug;138(2):352-7
pubmed: 26001328
Clin Cancer Res. 2020 Jun 1;26(11):2444-2451
pubmed: 32015021
Oncoimmunology. 2019 Sep 30;8(12):e1665460
pubmed: 31741762
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
Cancer Immunol Res. 2014 Jan;2(1):37-49
pubmed: 24535937
Clin Cancer Res. 2015 Jun 15;21(12):2840-50
pubmed: 25712684
Front Immunol. 2019 Oct 29;10:2393
pubmed: 31736936
Cancer Immunol Immunother. 2020 Dec;69(12):2477-2499
pubmed: 32561967
Nat Immunol. 2020 Oct;21(10):1160-1171
pubmed: 32747819
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31940588
Front Oncol. 2018 Dec 04;8:577
pubmed: 30564556
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
Oncogene. 2018 Apr;37(17):2285-2301
pubmed: 29398710
Gynecol Oncol. 2010 Mar;116(3):556-62
pubmed: 20006900
FEBS J. 2020 Dec;287(23):5218-5235
pubmed: 32239647
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366
Mod Pathol. 2009 Mar;22(3):393-402
pubmed: 19060844